Dror Ortho-Design, Inc. 8-K

What Happened
Dror Ortho-Design, Inc. announced on April 28, 2026 that it entered into a Securities Purchase Agreement to sell $275,000 in debentures in a private placement. The Debentures carry a 0% interest rate and mature on June 28, 2026 (holders may extend maturity by 60-day periods). If the company completes a future public offering, the outstanding debentures will automatically convert into common stock at the public offering price and related warrants may be issued to the purchasers.

Key Details

• Amount raised: $275,000 aggregate principal via Debentures, closing April 28, 2026.
• Debenture terms: 0% interest, maturity June 28, 2026; holders may extend maturity by successive 60‑day periods; customary events of default apply.
• Conversion: If a Public Offering occurs prior to maturity, outstanding debentures automatically convert into shares at the Public Offering per‑share price; converted shares receive the same terms as Public Offering shares.
• Warrants: Purchasers are entitled to purchase warrants tied to the Public Offering—Purchase Warrants and Additional Warrants—potentially equal to 100% or 150% (depending on whether debentures remain outstanding at the Public Offering) of related share amounts; warrants exercisable upon issuance, expire in 5 years, exercise price = Public Offering price.
• Ownership caps: Conversion/exercise limited so a holder plus affiliates cannot own more than 4.99% of outstanding shares post‑issuance (can be adjusted up to 9.99% with 61 days’ notice).
• Offering mechanics: Private placement relied on Section 4(a)(2) and Rule 506 exemptions; purchasers represented they are accredited investors; no general solicitation.

Why It Matters
This transaction provides Dror Ortho-Design with a small, short‑term cash infusion ($275K) without interest expense, but it creates contingent dilution tied to any future public offering because the debentures convert into stock at the offering price and could trigger issuance of substantial warrants. Retail investors should note the short maturity (June 28, 2026) and conversion mechanics: actual dilution depends on the terms and timing of any Public Offering. The agreement includes standard company representations and indemnities and was completed with accredited investors under private placement exemptions.